Search

Your search keyword '"Röllig, Christoph"' showing total 1,011 results
Start Over Author "Röllig, Christoph"
1,011 results on '"Röllig, Christoph"'

101. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Author

Röllig, Christoph, Serve, Hubert, Hüttmann, Andreas, Noppeney, Richard, Müller-Tidow, Carsten, Krug, Utz, Baldus, Claudia D, Brandts, Christian H, Kunzmann, Volker, Einsele, Hermann, Krämer, Alwin, Schäfer-Eckart, Kerstin, Neubauer, Andreas, Burchert, Andreas, Giagounidis, Aristoteles, Krause, Stefan W, Mackensen, Andreas, Aulitzky, Walter, Herbst, Regina, Hänel, Mathias, Kiani, Alexander, Frickhofen, Norbert, Kullmer, Johannes, Kaiser, Ulrich, Link, Hartmut, Geer, Thomas, Reichle, Albert, Junghanß, Christian, Repp, Roland, Heits, Frank, Dürk, Heinz, Hase, Jana, Klut, Ina-Maria, Illmer, Thomas, Bornhäuser, Martin, Schaich, Markus, Parmentier, Stefani, Görner, Martin, Thiede, Christian, von Bonin, Malte, Schetelig, Johannes, Kramer, Michael, Berdel, Wolfgang E, and Ehninger, Gerhard

Published
2015
Full Text
View/download PDF

102. Prognostic impact of CEBPAmutational subgroups in adult AML

Author

Georgi, Julia-Annabell, Stasik, Sebastian, Kramer, Michael, Meggendorfer, Manja, Röllig, Christoph, Haferlach, Torsten, Valk, Peter, Linch, David, Herold, Tobias, Duployez, Nicolas, Taube, Franziska, Middeke, Jan Moritz, Platzbecker, Uwe, Serve, Hubert, Baldus, Claudia D., Muller-Tidow, Carsten, Haferlach, Claudia, Koch, Sarah, Berdel, Wolfgang E., Woermann, Bernhard J., Krug, Utz, Braess, Jan, Hiddemann, Wolfgang, Spiekermann, Karsten, Boertjes, Emma L., Hills, Robert K., Burnett, Alan, Ehninger, Gerhard, Metzeler, Klaus, Rothenberg-Thurley, Maja, Dufour, Annika, Dombret, Hervé, Pautas, Cecile, Preudhomme, Claude, Fenwarth, Laurene, Bornhäuser, Martin, Gale, Rosemary, and Thiede, Christian

Abstract

Despite recent refinements in the diagnostic and prognostic assessment of CEBPAmutations in AML, several questions remain open, i.e. implications of different types of basic region leucin zipper (bZIP) mutations, the role of co-mutations and the allelic state. Using pooled primary data analysis on 1010 CEBPA-mutant adult AML patients, a comparison was performed taking into account the type of mutation (bZIP: either typical in-frame insertion/deletion (InDel) mutations (bZIPInDel), frameshift InDel or nonsense mutations inducing translational stop (bZIPSTOP) or single base-pair missense alterations (bZIPms), and transcription activation domain (TAD) mutations) and the allelic state (single (smCEBPA) vs. double mutant (dmCEBPA)). Only bZIPInDelpatients had significantly higher rates of complete remission and longer relapse free and overall survival (OS) compared with all other CEBPA-mutant subgroups. Moreover, co-mutations in bZIPInDelpatients (e.g. GATA2, FLT3, WT1as well as ELN2022 adverse risk aberrations) had no independent impact on OS, whereas in non-bZIPInDelpatients, grouping according to ELN2022 recommendations added significant prognostic information. In conclusion, these results demonstrate bZIPInDelmutations to be the major independent determinant of outcome in CEBPA-mutant AML, thereby refining current classifications according to WHO (including all dmCEBPAand smCEBPAbZIP) as well as ELN2022 and ICC recommendations (including CEBPAbZIPms).

Published
2024
Full Text
View/download PDF

103. Mutated IKZF1is an independent marker of adverse risk in acute myeloid leukemia

Author

Eckardt, Jan-Niklas, Stasik, Sebastian, Röllig, Christoph, Petzold, Andreas, Sauer, Tim, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, Zdenek, Mayer, Jiri, Oelschlägel, Uta, Berdel, Wolfgang E., Ehninger, Gerhard, Serve, Hubert, Müller-Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Dahl, Andreas, Schetelig, Johannes, Bornhäuser, Martin, Middeke, Jan Moritz, and Thiede, Christian

Abstract

Genetic lesions of IKZF1are frequent events and well-established markers of adverse risk in acute lymphoblastic leukemia. However, their function in the pathophysiology and impact on patient outcome in acute myeloid leukemia (AML) remains elusive. In a multicenter cohort of 1606 newly diagnosed and intensively treated adult AML patients, we found IKZF1alterations in 45 cases with a mutational hotspot at N159S. AML with mutated IKZF1was associated with alterations in RUNX1, GATA2, KRAS, KIT, SF3B1, and ETV6, while alterations of NPM1, TET2, FLT3-ITD, and normal karyotypes were less frequent. The clinical phenotype of IKZF1-mutated AML was dominated by anemia and thrombocytopenia. In both univariable and multivariable analyses adjusting for age, de novo and secondary AML, and ELN2022 risk categories, we found mutated IKZF1to be an independent marker of adverse risk regarding complete remission rate, event-free, relapse-free, and overall survival. The deleterious effects of mutated IKZF1also prevailed in patients who underwent allogeneic hematopoietic stem cell transplantation (n= 519) in both univariable and multivariable models. These dismal outcomes are only partially explained by the hotspot mutation N159S. Our findings suggest a role for IKZF1mutation status in AML risk modeling.

Published
2023
Full Text
View/download PDF

104. Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia

Author

Kayser, Sabine, primary, Martínez-Cuadrón, David, additional, Rodriguez-Veiga, Rebeca, additional, Hänel, Mathias, additional, Tormo, Mar, additional, Schäfer-Eckart, Kerstin, additional, Botella, Carmen, additional, Stölzel, Friedrich, additional, Del Castillo, Teresa Bernal, additional, Keller, Ulrich, additional, Rodriguez-Medina, Carlos, additional, Held, Gerhard, additional, Amigo, Maria-Luz, additional, Schliemann, Christoph, additional, Colorado, Mercedes, additional, Kaufmann, Martin, additional, Garcia, Manuel Barrios, additional, Krause, Stefan W., additional, Görner, Martin, additional, Jost, Edgar, additional, Steffen, Björn, additional, Zukunft, Sven, additional, Platzbecker, Uwe, additional, Ho, Anthony D., additional, Baldus, Claudia D., additional, Serve, Hubert, additional, Müller-Tidow, Carsten, additional, Thiede, Christian, additional, Bornhäuser, Martin, additional, Montesinos, Pau, additional, Röllig, Christoph, additional, and Schlenk, Richard F., additional

Published
2023
Full Text
View/download PDF

105. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia

Author

Bornhäuser, Martin, primary, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Röllig, Christoph, additional, Kramer, Michael, additional, Glass, Bertram, additional, Platzbecker, Uwe, additional, Burchert, Andreas, additional, Hänel, Mathias, additional, Müller, Lutz P., additional, Klein, Stefan, additional, Bug, Gesine, additional, Beelen, Dietrich, additional, Rösler, Wolf, additional, Schäfer-Eckart, Kerstin, additional, Schmid, Christoph, additional, Jost, Edgar, additional, Lenz, Georg, additional, Tischer, Johanna, additional, Spiekermann, Karsten, additional, Pfirrmann, Markus, additional, Serve, Hubert, additional, Stölzel, Friedrich, additional, Alakel, Nael, additional, Middeke, Jan Moritz, additional, Thiede, Christian, additional, Ehninger, Gerhard, additional, Berdel, Wolfgang E., additional, and Stelljes, Matthias, additional

Published
2023
Full Text
View/download PDF

106. Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial

Author

Ruhnke, Leo, primary, Röllig, Christoph, additional, Herold, Sylvia, additional, Sauer, Tim, additional, Brandts, Christian H, additional, Steffen, Björn, additional, Schäfer-Eckart, Kerstin, additional, Krause, Stefan W, additional, Hänel, Mathias, additional, Reichle, Albrecht, additional, Scholl, Sebastian, additional, Neubauer, Andreas, additional, Mikesch, Jan-Henrik, additional, Schetelig, Johannes, additional, Stölzel, Friedrich, additional, Kramer, Michael, additional, Haake, Annett, additional, Frimmel, Julia, additional, Krämer, Alwin, additional, Schlenk, Richard, additional, Platzbecker, Uwe, additional, Serve, Hubert, additional, Baldus, Claudia D, additional, Müller-Tidow, Carsten, additional, Aust, Daniela, additional, Bornhäuser, Martin, additional, Ehninger, Gerhard, additional, and Thiede, Christian, additional

Published
2023
Full Text
View/download PDF

108. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

Author

Stölzel, Friedrich, primary, Fordham, Sarah E., additional, Nandana, Devi, additional, Lin, Wei-Yu, additional, Blair, Helen, additional, Elstob, Claire, additional, Bell, Hayden L., additional, Mohr, Brigitte, additional, Ruhnke, Leo, additional, Kunadt, Desiree, additional, Dill, Claudia, additional, Allsop, Daniel, additional, Piddock, Rachel, additional, Soura, Emmanouela-Niki, additional, Park, Catherine, additional, Fadly, Mohd, additional, Rahman, Thahira, additional, Alharbi, Abrar, additional, Wobus, Manja, additional, Altmann, Heidi, additional, Röllig, Christoph, additional, Wagenführ, Lisa, additional, Jones, Gail L., additional, Menne, Tobias, additional, Jackson, Graham H., additional, Marr, Helen J., additional, Fitzgibbon, Jude, additional, Onel, Kenan, additional, Meggendorfer, Manja, additional, Robinson, Amber, additional, Bziuk, Zuzanna, additional, Bowes, Emily, additional, Heidenreich, Olaf, additional, Haferlach, Torsten, additional, Villar, Sara, additional, Ariceta, Beñat, additional, Diaz, Rosa Ayala, additional, Altschuler, Steven J., additional, Wu, Lani F., additional, Prosper, Felipe, additional, Montesinos, Pau, additional, Martinez-Lopez, Joaquin, additional, Bornhäuser, Martin, additional, and Allan, James M., additional

Published
2023
Full Text
View/download PDF

109. A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia

Author

Zhou, Fengbiao, primary, Aroua, Nesrine, additional, Liu, Yi, additional, Rohde, Christian, additional, Cheng, Jingdong, additional, Wirth, Anna-Katharina, additional, Fijalkowska, Daria, additional, Göllner, Stefanie, additional, Lotze, Michelle, additional, Yun, Haiyang, additional, Yu, Xiaobing, additional, Pabst, Caroline, additional, Sauer, Tim, additional, Oellerich, Thomas, additional, Serve, Hubert, additional, Röllig, Christoph, additional, Bornhäuser, Martin, additional, Thiede, Christian, additional, Baldus, Claudia, additional, Frye, Michaela, additional, Raffel, Simon, additional, Krijgsveld, Jeroen, additional, Jeremias, Irmela, additional, Beckmann, Roland, additional, Trumpp, Andreas, additional, and Müller-Tidow, Carsten, additional

Published
2023
Full Text
View/download PDF

112. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients with Intermediate-Risk Acute Myeloid Leukemia : A Randomized Clinical Trial

Author

Bornhäuser, Martin, Schliemann, Christoph, Schetelig, Johannes, Röllig, Christoph, Kramer, Michael, Glass, Bertram, Platzbecker, Uwe, Burchert, Andreas, Hänel, Mathias, Müller, Lutz P., Klein, Stefan, Bug, Gesine, Beelen, Dietrich, Rösler, Wolf, Schäfer-Eckart, Kerstin, Schmid, Christoph, Jost, Edgar, Lenz, Georg, Tischer, Johanna, Spiekermann, Karsten, Pfirrmann, Markus, Serve, Hubert, Stölzel, Friedrich, Alakel, Nael, Middeke, Jan Moritz, Thiede, Christian, Ehninger, Gerhard, Berdel, Wolfgang E., and Stelljes, Matthias

Subjects
Cancer Research, Oncology, Medizin
Abstract

ImportanceThe ideal postremission strategy in intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR) has been a matter of debate.ObjectiveTo explore the optimal therapy for patients with intermediate-risk AML after first complete remission.Design, Settings, and ParticipantsThis investigator-initiated, open-label, 2-armed, phase 3 randomized clinical trial assessed patients at 16 hospitals in Germany from February 2, 2011, until July 1, 2018. Key eligibility criteria included cytogenetically defined intermediate-risk AML according to Medical Research Council classification, first CR or CR with incomplete blood cell count recovery after conventional induction therapy, age of 18 to 60 years, and availability of a human leukocyte antigen (HLA)–matched sibling or unrelated donor. A detailed statistical analysis plan was written and finalized on July 7, 2020. Data were exported for analysis on April 13, 2021.InterventionsPatients were randomized 1:1 to receive allogeneic hematopoietic cell transplantation (HCT) or high-dose cytarabine for consolidation and salvage HCT only in case of relapse. Strata for randomization included age (18-40 vs 41-60 years), NPM1 and CEBPA variation status, and donor type (unrelated vs related).Main Outcomes and MeasuresEnd points included overall-survival as the primary outcome and disease-free survival, cumulative incidence of relapse, treatment-related mortality, and quality of life measured according to the Medical Outcomes Study 36-Item Short-Form Health Survey as secondary outcomes.ResultsA total of 143 patients (mean [SD] age, 48.2 [9.8] years; 81 [57%] male) with AML who fulfilled the eligibility criteria were randomized. In the intention-to-treat analysis, the probability of survival at 2 years was 74% (95% CI, 62%-83%) after primary allogeneic HCT and 84% (95% CI, 73%-92%) after consolidation chemotherapy (P = .22). Disease-free survival after HCT at 2 years was 69% (95% CI, 57%-80%) compared with 40% (95% CI, 28%-53%) after consolidation chemotherapy (P = .001). Allogeneic HCT during the first CR was associated with a cumulative incidence of relapse at 2 years of 20% (95% CI, 13%-31%) compared with 58% (95% CI, 47%-71%; P P = .005). Similar outcomes were observed when analyses were confined to the 96 patients at intermediate risk according to the European Leukemia Network classification. Most importantly, all 41 patients relapsing after consolidation chemotherapy (36 hematologic, 4 molecular, and 1 extramedullary) proceeded to allogeneic HCT. No significant differences in health-related quality of life measures were observed between groups.Conclusions and RelevancePrimary allogeneic HCT during first CR was not associated with superior overall survival compared with consolidation chemotherapy in patients 60 years or younger with intermediate-risk AML during the first CR and an available donor.Trial RegistrationClinicalTrials.gov Identifier: NCT01246752

Published
2023

114. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)

Author

Steinhäuser, Sophie, primary, Silva, Patricia, additional, Lenk, Lennart, additional, Beder, Thomas, additional, Hartmann, Alina, additional, Hänzelmann, Sonja, additional, Fransecky, Lars, additional, Neumann, Martin, additional, Bastian, Lorenz, additional, Lipinski, Simone, additional, Richter, Kathrin, additional, Bultmann, Miriam, additional, Hübner, Emely, additional, Xia, Shuli, additional, Röllig, Christoph, additional, Vogiatzi, Fotini, additional, Schewe, Denis Martin, additional, Yumiceba, Veronica, additional, Schultz, Kristin, additional, Spielmann, Malte, additional, and Baldus, Claudia Dorothea, additional

Published
2022
Full Text
View/download PDF

115. Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Author

Röllig, Christoph, primary, Steffen, Björn, additional, Schliemann, Christoph, additional, Mikesch, Jan-Henrik, additional, Alakel, Nael, additional, Herbst, Regina, additional, Haenel, Mathias, additional, Noppeney, Richard, additional, Hanoun, Maher, additional, Kaufmann, Martin, additional, Racil, Zdenek, additional, Schäfer-Eckart, Kerstin, additional, Sauer, Tim, additional, Neubauer, Andreas, additional, Baldus, Claudia D., additional, Mertova, Jolana, additional, Jost, Edgar, additional, Niemann, Dirk, additional, Novak, Jan, additional, Krause, Stefan W., additional, Scholl, Sebastian, additional, Hochhaus, Andreas, additional, Held, Gerhard, additional, Szotkowski, Tomáš, additional, Schmid, Christoph, additional, Rank, Andreas, additional, Fransecky, Lars, additional, Kramer, Michael, additional, Fiebig, Frank, additional, Haake, Annett, additional, Stoelzel, Friedrich, additional, Schetelig, Johannes, additional, Middeke, Jan Moritz, additional, Platzbecker, Uwe, additional, Thiede, Christian, additional, Müller-Tidow, Carsten, additional, Berdel, Wolfgang E., additional, Serve, Hubert, additional, Ehninger, Gerhard, additional, Mayer, Jiří, additional, and Bornhaeuser, Martin, additional

Published
2022
Full Text
View/download PDF

116. In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Author

Stelljes, Matthias, primary, Middeke, Jan Moritz, additional, Bug, Gesine, additional, Wagner, Eva-Maria, additional, Mueller, Lutz Peter, additional, Christoph, Schmid, additional, Krause, Stefan W., additional, Bethge, Wolfgang, additional, Jost, Edgar, additional, Platzbecker, Uwe, additional, Klein, Stefan, additional, Schubert, Jörg, additional, Niederland, Judith, additional, Kaufmann, Martin, additional, Schäfer-Eckart, Kerstin, additional, Schaich, Markus, additional, Baldauf, Henning, additional, Stölzel, Friedrich, additional, Petzold, Cathleen, additional, Röllig, Christoph, additional, Alakel, Nael, additional, Steffen, Björn, additional, Hauptrock, Beate, additional, Reicherts, Christian, additional, Schliemann, Christoph, additional, Serve, Hubert, additional, Schmidt, Alexander H., additional, Bornhäuser, Martin, additional, Mikesch, Jan-Henrik, additional, and Schetelig, Johannes, additional

Published
2022
Full Text
View/download PDF

117. Fast-Track Measurable Residual Disease Detection By Multiparametric Flow Cytometry in Acute Myeloid Leukemia before Allogeneic Hematopoietic Cell Transplantation

Author

Röhnert, Maximilian Alexander, primary, Kramer, Michael, additional, Schadt, Jonas, additional, Ensel, Philipp, additional, Röllig, Christoph, additional, Schetelig, Johannes, additional, Stölzel, Friedrich, additional, Bornhaeuser, Martin, additional, Oelschlägel, Uta, additional, and von Bonin, Malte, additional

Published
2022
Full Text
View/download PDF

118. Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction

Author

Döhner, Konstanze, primary, Döhner, Hartmut, additional, Weber, Daniela, additional, Kapp-Schwoerer, Silke, additional, Gilkes, Amanda, additional, Thomas, Ian, additional, Johnson, Sean, additional, Potter, Nicola, additional, Bevan, Yana, additional, Othman, Jad, additional, Russell, Nigel H., additional, Röllig, Christoph, additional, Thiede, Christian, additional, Bornhaeuser, Martin, additional, Oellerich, Thomas, additional, Elder, Jenna, additional, Carvajal, Luis A., additional, To, Zung, additional, DiMartino, Jorge, additional, and Dillon, Richard, additional

Published
2022
Full Text
View/download PDF

119. Prevalence, Clinical and Molecular Features, and Prognostic Value of Tetraploidy/Near-Tetraploidy in Patients with Acute Myeloid Leukemia

Author

Ruhnke, Leo, primary, Frimmel, Julia, additional, Röllig, Christoph, additional, Mohr, Brigitte, additional, Altmann, Heidi, additional, Poitz, David, additional, Zukunft, Sven, additional, Schranz, Katrin, additional, Vosberg, Sebastian, additional, Spiekermann, Karsten, additional, von Bergwelt, Michael, additional, Jost, Edgar, additional, Dressler, Sabine, additional, Schäfer-Eckart, Kerstin, additional, Chavakis, Triantafyllos, additional, Aust, Daniela, additional, Jöhrens, Korinna, additional, Baretton, Gustavo, additional, Bornhäuser, Martin, additional, Greif, Philipp A., additional, Stölzel, Friedrich, additional, Herold, Sylvia, additional, and Wagenführ, Lisa, additional

Published
2022
Full Text
View/download PDF

120. Proteomic Characterization of Acute Myeloid Leukemia

Author

Wolf, Sebastian, primary, Jayavelu, Ashok Kumar, additional, Buettner, Florian, additional, Alexe, Gabriela, additional, Häupl, Björn, additional, Schneider, Constanze, additional, Wilke, Anne C, additional, Zindel, Alena, additional, Jahn, Dominique, additional, Splettstoesser, Bianca, additional, Enssle, Julius Christoph, additional, Cremer, Anjali, additional, Röllig, Christoph, additional, Thiede, Christian, additional, Steffen, Björn, additional, Bornhäuser, Martin, additional, Urlaub, Henning, additional, Stegmaier, Kimberly, additional, Serve, Hubert, additional, Mann, Matthias, additional, and Oellerich, Thomas, additional

Published
2022
Full Text
View/download PDF

121. Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

Author

Georgi, Julia-Annabell, primary, Stasik, Sebastian, additional, Zukunft, Sven, additional, Hartwig, Marita, additional, Röllig, Christoph, additional, Oelschlaegel, Uta, additional, Krug, Utz, additional, Sauer, Tim, additional, Scholl, Sebastian, additional, Hochhaus, Andreas, additional, Brümmendorf, Tim H, additional, Naumann, Ralph, additional, Steffen, Björn, additional, Einsele, Hermann, additional, Schaich, Markus, additional, Burchert, Andreas, additional, Neubauer, Andreas, additional, Schaefer-Eckart, Kerstin, additional, Schliemann, Christoph, additional, Krause, Stefan W., additional, Haenel, Mathias, additional, Noppeney, Richard, additional, Kaiser, Ulrich, additional, Baldus, Claudia D., additional, Kaufmann, Martin, additional, Müller-Tidow, Carsten, additional, Platzbecker, Uwe, additional, Berdel, Wolfgang E., additional, Serve, Hubert, additional, Ehninger, Gerhard, additional, Bornhaeuser, Martin, additional, Schetelig, Johannes, additional, Kroschinsky, Frank P., additional, and Thiede, Christian, additional

Published
2022
Full Text
View/download PDF

122. Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Author

Röllig, Christoph, primary, Fransecky, Lars, additional, Hanoun, Maher, additional, Steffen, Björn, additional, Kraus, Sabrina, additional, Schliemann, Christoph, additional, Haake, Annett, additional, Fiebig, Frank, additional, Zukunft, Sven, additional, Alakel, Nael, additional, Middeke, Jan Moritz, additional, Bornhaeuser, Martin, additional, Stoelzel, Friedrich, additional, Schetelig, Johannes, additional, Ruhnke, Leo, additional, Kramer, Michael, additional, Von Bonin, Malte, additional, Röhnert, Maximilian Alexander, additional, Oelschlägel, Uta, additional, Baldus, Claudia D., additional, Serve, Hubert, additional, and Wermke, Martin, additional

Published
2022
Full Text
View/download PDF

123. Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies

Author

Kirschner, Martin, primary, Rolles, Benjamin, additional, Crysandt, Martina, additional, Röllig, Christoph, additional, Stölzel, Friedrich, additional, Kramer, Michael, additional, Bornhäuser, Martin, additional, Serve, Hubert, additional, Platzbecker, Uwe, additional, Müller-Tidow, Carsten, additional, Kricheldorf, Kim, additional, Vieri, Margherita, additional, Begemann, Matthias, additional, Maurer, Angela, additional, Wlodarski, Marcin W., additional, Sahoo, Sushree S., additional, Brümmendorf, Tim H., additional, Jost, Edgar, additional, and Beier, Fabian, additional

Published
2022
Full Text
View/download PDF

124. Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Author

Middeke, Jan M., Fang, Min, Cornelissen, Jan J., Mohr, Brigitte, Appelbaum, Frederick R., Stadler, Michael, Sanz, Jaime, Baurmann, Herrad, Bug, Gesine, Schäfer-Eckart, Kerstin, Hegenbart, Ute, Bochtler, Tilmann, Röllig, Christoph, Stölzel, Friedrich, Walter, Roland B., Ehninger, Gerhard, Bornhäuser, Martin, Löwenberg, Bob, and Schetelig, Johannes

Published
2014
Full Text
View/download PDF

126. Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL)

Author

Kossak-Roth, Ute, Saußele, Susanne, Aul, Carlo, Büchner, Thomas, Döhner, Hartmut, Dugas, Martin, Ehninger, Gerhard, Ganser, Arnold, Giagounidis, Aristoteles, Gökbuget, Nicola, Griesshammer, Martin, Hasford, Jörg, Heuser, Michael, Hiddemann, Wolfgang, Hochhaus, Andreas, Hoelzer, Dieter, Niederwieser, Dietger, Reiter, Andreas, Röllig, Christoph, and Hehlmann, Rüdiger

Published
2016
Full Text
View/download PDF

127. Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with intermediate-risk - results of the randomized ETAL-1 trial

Author

Bornhauser, Martin, primary, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Röllig, Christoph, additional, Kramer, Michael, additional, Glass, Bertram, additional, Platzbecker, Uwe, additional, Burchert, Andreas, additional, Hänel, Mathias, additional, Muller, Lutz, additional, Klein, Stefan, additional, Bug, Gesine, additional, Beelen, Dietrich, additional, Rösler, Wolf, additional, Schäfer-Eckart, Kerstin, additional, Schmid, Christoph, additional, Jost, Edgar, additional, Lenz, Georg, additional, Tischer, Johanna, additional, Spiekermann, Karsten, additional, Pfirrmann, Markus, additional, Serve, Hubert, additional, Stölzel, Friedrich, additional, Alakel, Nael, additional, Middeke, Jan Moritz, additional, Thiede, Christian, additional, Ehninger, Gerhard, additional, Berdel, Wolfgang, additional, and Stelljes, Matthias, additional

Published
2022
Full Text
View/download PDF

128. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning

Author

Eckardt, Jan-Niklas, primary, Röllig, Christoph, additional, Metzeler, Klaus, additional, Kramer, Michael, additional, Stasik, Sebastian, additional, Georgi, Julia-Annabell, additional, Heisig, Peter, additional, Spiekermann, Karsten, additional, Krug, Utz, additional, Braess, Jan, additional, Görlich, Dennis, additional, Sauerland, Cristina M., additional, Woermann, Bernhard, additional, Herold, Tobias, additional, Berdel, Wolfgang E., additional, Hiddemann, Wolfgang, additional, Kroschinsky, Frank, additional, Schetelig, Johannes, additional, Platzbecker, Uwe, additional, Müller-Tidow, Carsten, additional, Sauer, Tim, additional, Serve, Hubert, additional, Baldus, Claudia, additional, Schäfer-Eckart, Kerstin, additional, Kaufmann, Martin, additional, Krause, Stefan, additional, Hänel, Mathias, additional, Schliemann, Christoph, additional, Hanoun, Maher, additional, Thiede, Christian, additional, Bornhäuser, Martin, additional, Wendt, Karsten, additional, and Middeke, Jan Moritz, additional

Published
2022
Full Text
View/download PDF

129. Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD

Author

Jaramillo, Sonia, primary, Cornet, Lucian Le, additional, Kratzmann, Markus, additional, Krisam, Johannes, additional, Görner, Martin, additional, Hänel, Mathias, additional, Röllig, Christoph, additional, Wass, Maxi, additional, Scholl, Sebastian, additional, Ringhoffer, Mark, additional, Reichart, Alexander, additional, Steffen, Björn, additional, Kayser, Sabine, additional, Mikesch, Jan-Henrik, additional, Schaefer-Eckart, Kerstin, additional, Schubert, Jörg, additional, Geer, Thomas, additional, Martin, Sonja, additional, Kieser, Meinhard, additional, Sauer, Tim, additional, Kriegsmann, Katharina, additional, Hundemer, Michael, additional, Serve, Hubert, additional, Bornhäuser, Martin, additional, Müller-Tidow, Carsten, additional, and Schlenk, Richard F., additional

Published
2022
Full Text
View/download PDF

130. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Author

Kayser, Sabine, primary, Martínez-Cuadrón, David, additional, Hanoun, Maher, additional, Stölzel, Friedrich, additional, Gil, Cristina, additional, Reinhardt, H. Christian, additional, Aguiar, Eliana, additional, Schäfer-Eckart, Kerstin, additional, Burgues, Juan Miguel Bergua, additional, Steffen, Björn, additional, Bernal, Teresa, additional, Krause, Stefan W., additional, Riaza, Rosalía, additional, Schliemann, Christoph, additional, Cervera, Jose, additional, Kaufmann, Martin, additional, Torres-Miñana, Laura, additional, Hänel, Mathias, additional, Acuña-Cruz, Evelyn, additional, Jost, Edgar, additional, Algarra, Jesus Lorenzo, additional, Crysandt, Martina, additional, Fransecky, Lars, additional, Cornago-Navascues, Javier, additional, Kraus, Sabrina, additional, Martinez-Lopez, Joaquin, additional, Einsele, Hermann, additional, Niemann, Dirk, additional, Neubauer, Andreas, additional, Seggewiß-Bernhardt, Ruth, additional, Scholl, Sebastian, additional, Klein, Stefan A., additional, Schmid, Christoph, additional, Schaich, Markus, additional, Schmidt-Hieber, Martin, additional, Zukunft, Sven, additional, Ho, Anthony D., additional, Platzbecker, Uwe, additional, Baldus, Claudia D., additional, Müller-Tidow, Carsten, additional, Thiede, Christian, additional, Bornhäuser, Martin, additional, Serve, Hubert, additional, Levis, Mark, additional, Montesinos, Pau, additional, Röllig, Christoph, additional, and Schlenk, Richard F., additional

Published
2022
Full Text
View/download PDF

131. Intensified cytarabine dose during consolidation in AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

Author

Hanoun, Maher, primary, Ruhnke, Leo, additional, Kramer, Michael, additional, Hanoun, Christine, additional, Schäfer-Eckart, Kerstin, additional, Steffen, Björn, additional, Sauer, Tim, additional, Krause, Stefan, additional, Schliemann, Christoph, additional, Mikesch, Jan-Henrik, additional, Kaufmann, Martin, additional, Haenel, Mathias, additional, Jost, Edgar, additional, Bruemmendorf, Tim, additional, Fransecky, LArs, additional, Kraus, Sabrina, additional, Einsele, Hermann, additional, Niemann, Dirk, additional, Neubauer, Andreas, additional, Kullmer, Johannes, additional, Seggewiss-Bernhard, Ruth, additional, Goerner, Martin, additional, Held, Gerhard, additional, Kaiser, Ulrich, additional, Scholl, Sebastian, additional, Hochhaus, Andreas, additional, Reinhardt, Hans, additional, Platzbecker, Uwe, additional, Baldus, Claudia, additional, Müller-Tidow, Carsten, additional, Bornhäuser, Martin, additional, Serve, Hubert, additional, and Röllig, Christoph, additional

Published
2022
Full Text
View/download PDF

132. Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study.

Author

Daver, Naval Guastad, primary, Stevens, Don A., additional, Hou, Jing-Zhou, additional, Yamauchi, Takahiro, additional, Moshe, Yakir, additional, Fong, Chun Yew, additional, Marzocchetti, Angela, additional, Adamec, Ryan, additional, Patel, Maulik, additional, Lambert, Stacie, additional, Wu, Kevin, additional, and Röllig, Christoph, additional

Published
2022
Full Text
View/download PDF

135. Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD

Author

Stasik, Sebastian, Kramer, Michael, Zukunft, Sven, Röllig, Christoph, Baldus, Claudia D., Platzbecker, Uwe, Serve, Hubert, Müller-Tidow, Carsten, Schäfer-Eckart, Kerstin, Kaufmann, Martin, Krause, Stefan, Sauer, Tim, Hänel, Mathias, Neubauer, Andreas, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, Middeke, Jan M., and Thiede, Christian

Subjects
body regions, Cancer Research, Oncology, hemic and lymphatic diseases, embryonic structures, hemic and immune systems, ddc:610, psychological phenomena and processes
Abstract

FLT3-ITD mutations are common druggable alterations in patients with acute myeloid leukemia (AML) and associated with poor prognosis. Beside typical ITD mutations, point mutations and deletions in the juxtamembrane domain (JMD) have been observed. However, due to the low frequency of these alterations, there is only limited information on molecular and clinical associations. To evaluate the prognostic impact of non-ITD mutations in the FLT3 JMD region, we analyzed a large cohort of 1,539 adult AML patients treated in different protocols of the Study Alliance Leukemia, using next-generation sequencing. Non-ITD point mutations and deletions within the FLT3 JMD were identified with a prevalence of ~1.23% (n = 19). Both FLT3-ITD and non-ITD mutations were associated with a higher rate of NPM1 (42%–61%; p < 0.001) and DNMT3A mutations (37%–43%; p < 0.001), as well as an increased percentage of peripheral blood (54%–65%) and bone marrow blast cells (74%; p < 0.001), compared to FLT3-wild-type patients. Most significantly, AML patients with FLT3 non-ITD mutations had a higher rate of concomitant KMT2A-PTD mutations (37.5%; p < 0.001) as compared to FLT3-ITD (7%) or FLT3-wild-type cases (4.5%). In a multivariable analysis, FLT3 non-ITD mutations were not an independent prognostic factor. However, patients with dual FLT3 non-ITD and KMT2A-PTD mutations showed a trend for inferior outcome, which points at a functional interaction in this subset of AML.

Published
2022

136. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

Author

Eckardt, Jan‑Niklas, Schmittmann, Tim, Riechert, Sebastian, Kramer, Michael, Shekh Sulaiman, Anas, Sockel, Katja, Kroschinsky, Frank, Schetelig, Johannes, Wagenführ, Lisa, Schuler, Ulrich, Platzbecker, Uwe, Thiede, Christian, Stölzel, Friedrich, Röllig, Christoph, Bornhäuser, Martin, Wendt, Karsten, Middeke, Jan Moritz, Eckardt, Jan‑Niklas, Schmittmann, Tim, Riechert, Sebastian, Kramer, Michael, Shekh Sulaiman, Anas, Sockel, Katja, Kroschinsky, Frank, Schetelig, Johannes, Wagenführ, Lisa, Schuler, Ulrich, Platzbecker, Uwe, Thiede, Christian, Stölzel, Friedrich, Röllig, Christoph, Bornhäuser, Martin, Wendt, Karsten, and Middeke, Jan Moritz

Abstract

Background: Acute promyelocytic leukemia (APL) is considered a hematologic emergency due to high risk of bleeding and fatal hemorrhages being a major cause of death. Despite lower death rates reported from clinical trials, patient registry data suggest an early death rate of 20%, especially for elderly and frail patients. Therefore, reliable diagnosis is required as treatment with differentiation-inducing agents leads to cure in the majority of patients. However, diagnosis commonly relies on cytomorphology and genetic confirmation of the pathognomonic t(15;17). Yet, the latter is more time consuming and in some regions unavailable. - Methods: In recent years, deep learning (DL) has been evaluated for medical image recognition showing outstanding capabilities in analyzing large amounts of image data and provides reliable classification results. We developed a multi-stage DL platform that automatically reads images of bone marrow smears, accurately segments cells, and subsequently predicts APL using image data only. We retrospectively identified 51 APL patients from previous multicenter trials and compared them to 1048 non-APL acute myeloid leukemia (AML) patients and 236 healthy bone marrow donor samples, respectively. - Results: Our DL platform segments bone marrow cells with a mean average precision and a mean average recall of both 0.97. Further, it achieves high accuracy in detecting APL by distinguishing between APL and non-APL AML as well as APL and healthy donors with an area under the receiver operating characteristic of 0.8575 and 0.9585, respectively, using visual image data only. - Conclusions: Our study underlines not only the feasibility of DL to detect distinct morphologies that accompany a cytogenetic aberration like t(15;17) in APL, but also shows the capability of DL to abstract information from a small medical data set, i. e. 51 APL patients, and infer correct predictions. This demonstrates the suitability of DL to assist in the diagnosis of rare ca

Published
2022

137. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Author

Eckardt, Jan‑Niklas, Stölzel, Friedrich, Kunadt, Desiree, Röllig, Christoph, Stasik, Sebastian, Wagenführ, Lisa, Jöhrens, Korinna, Kuithan, Friederike, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, Zdenek, Mayer, Jiri, Kroschinsky, Frank, Berdel, Wolfgang E., Ehninger, Gerhard, Serve, Hubert, Müller‑Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Schetelig, Johannes, Bornhäuser, Martin, Thiede, Christian, Middeke, Jan Moritz, Eckardt, Jan‑Niklas, Stölzel, Friedrich, Kunadt, Desiree, Röllig, Christoph, Stasik, Sebastian, Wagenführ, Lisa, Jöhrens, Korinna, Kuithan, Friederike, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, Zdenek, Mayer, Jiri, Kroschinsky, Frank, Berdel, Wolfgang E., Ehninger, Gerhard, Serve, Hubert, Müller‑Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Schetelig, Johannes, Bornhäuser, Martin, Thiede, Christian, and Middeke, Jan Moritz

Abstract

Background: Extramedullary manifestations (EM) are rare in acute myeloid leukemia (AML) and their impact on clinical outcomes is controversially discussed. - Methods: We retrospectively analyzed a large multi-center cohort of 1583 newly diagnosed AML patients, of whom 225 (14.21%) had EM. - Results: AML patients with EM presented with significantly higher counts of white blood cells (p < 0.0001), peripheral blood blasts (p < 0.0001), bone marrow blasts (p = 0.019), and LDH (p < 0.0001). Regarding molecular genetics, EM AML was associated with mutations of NPM1 (OR: 1.66, p < 0.001), FLT3-ITD (OR: 1.72, p < 0.001) and PTPN11 (OR: 2.46, p < 0.001). With regard to clinical outcomes, EM AML patients were less likely to achieve complete remissions (OR: 0.62, p = 0.004), and had a higher early death rate (OR: 2.23, p = 0.003). Multivariable analysis revealed EM as an independent risk factor for reduced overall survival (hazard ratio [HR]: 1.43, p < 0.001), however, for patients who received allogeneic hematopoietic cell transplantation (HCT) survival did not differ. For patients bearing EM AML, multivariable analysis unveiled mutated TP53 and IKZF1 as independent risk factors for reduced event-free (HR: 4.45, p < 0.001, and HR: 2.05, p = 0.044, respectively) and overall survival (HR: 2.48, p = 0.026, and HR: 2.63, p = 0.008, respectively). - Conclusion: Our analysis represents one of the largest cohorts of EM AML and establishes key molecular markers linked to EM, providing new evidence that EM is associated with adverse risk in AML and may warrant allogeneic HCT in eligible patients with EM.

Published
2022

138. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Author

Middeke, Jan Moritz, Metzeler, Klaus Hans, Röllig, Christoph, Krämer, Michael, Eckardt, Jan-Niklas, Stasik, Sebastian, Greif, Philipp, Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Brümmendorf, Tim Henrik, Naumann, Ralph, Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Kaufmann, Martin, Kunadt, Désirée, Wörmann, Bernhard, Sockel, Katja, Bonin, von Malte, Herold, Tobias, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Baldus, Claudia, Ehninger, Gerhard, Schetelig, Johannes, Hiddemann, Wolfgang, Bornhäuser, Martin, Stölzel, Friedrich, Thiede, Christian, Middeke, Jan Moritz, Metzeler, Klaus Hans, Röllig, Christoph, Krämer, Michael, Eckardt, Jan-Niklas, Stasik, Sebastian, Greif, Philipp, Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Brümmendorf, Tim Henrik, Naumann, Ralph, Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Kaufmann, Martin, Kunadt, Désirée, Wörmann, Bernhard, Sockel, Katja, Bonin, von Malte, Herold, Tobias, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Baldus, Claudia, Ehninger, Gerhard, Schetelig, Johannes, Hiddemann, Wolfgang, Bornhäuser, Martin, Stölzel, Friedrich, and Thiede, Christian

Abstract

Mutations of the isocitrate dehydrogenase-1 (IDH1) and IDH2 genes are among the most frequent alterations in acute myeloid leukemia (AML) and can be found in ∼20% of patients at diagnosis. Among 4930 patients (median age, 56 years; interquartile range, 45-66) with newly diagnosed, intensively treated AML, we identified IDH1 mutations in 423 (8.6%) and IDH2 mutations in 575 (11.7%). Overall, there were no differences in response rates or survival for patients with mutations in IDH1 or IDH2 compared with patients without mutated IDH1/2. However, distinct clinical and comutational phenotypes of the most common subtypes of IDH1/2 mutations could be associated with differences in outcome. IDH1-R132C was associated with increased age, lower white blood cell (WBC) count, less frequent comutation of NPM1 and FLT3 internal tandem mutation (ITD) as well as with lower rate of complete remission and a trend toward reduced overall survival (OS) compared with other IDH1 mutation variants and wild-type (WT) IDH1/2. In our analysis, IDH2-R172K was associated with significantly lower WBC count, more karyotype abnormalities, and less frequent comutations of NPM1 and/or FLT3-ITD. Among patients within the European LeukemiaNet 2017 intermediate- and adverse-risk groups, relapse-free survival and OS were significantly better for those with IDH2-R172K compared with WT IDH, providing evidence that AML with IDH2-R172K could be a distinct entity with a specific comutation pattern and favorable outcome. In summary, the presented data from a large cohort of patients with IDH1/2 mutated AML indicate novel and clinically relevant findings for the most common IDH mutation subtypes.

Published
2022

139. Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial

Author

Röllig, Christoph, Schäfer-Eckardt, Kerstin, Hänel, Matthias, Kramer, Michael, Schaich, Markus, Thiede, Christian, Oelschlägel, Uta, Mohr, Brigitte, Wagner, Thomas, Einsele, Hermann, Krause, Stefan W., Bodenstein, Heinrich, Martin, Sonja, Stuhlmann, Reingard, Ho, Antony D., Bornhäuser, Martin, Ehninger, Gerhard, Schuler, Ulrich, and Platzbecker, Uwe

Published
2015
Full Text
View/download PDF

141. The proteogenomic subtypes of acute myeloid leukemia

Author

Jayavelu, Ashok Kumar, primary, Wolf, Sebastian, additional, Buettner, Florian, additional, Alexe, Gabriela, additional, Häupl, Björn, additional, Comoglio, Federico, additional, Schneider, Constanze, additional, Doebele, Carmen, additional, Fuhrmann, Dominik C., additional, Wagner, Sebastian, additional, Donato, Elisa, additional, Andresen, Carolin, additional, Wilke, Anne C., additional, Zindel, Alena, additional, Jahn, Dominique, additional, Splettstoesser, Bianca, additional, Plessmann, Uwe, additional, Münch, Silvia, additional, Abou-El-Ardat, Khali, additional, Makowka, Philipp, additional, Acker, Fabian, additional, Enssle, Julius C., additional, Cremer, Anjali, additional, Schnütgen, Frank, additional, Kurrle, Nina, additional, Chapuy, Björn, additional, Löber, Jens, additional, Hartmann, Sylvia, additional, Wild, Peter J., additional, Wittig, Ilka, additional, Hübschmann, Daniel, additional, Kaderali, Lars, additional, Cox, Jürgen, additional, Brüne, Bernhard, additional, Röllig, Christoph, additional, Thiede, Christian, additional, Steffen, Björn, additional, Bornhäuser, Martin, additional, Trumpp, Andreas, additional, Urlaub, Henning, additional, Stegmaier, Kimberly, additional, Serve, Hubert, additional, Mann, Matthias, additional, and Oellerich, Thomas, additional

Published
2022
Full Text
View/download PDF

142. sj-docx-1-tah-10.1177_20406207221115005 – Supplemental material for Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation

Author

Kunadt, Desiree, Herold, Sylvia, Poitz, David, Wagenführ, Lisa, Kretschmann, Theresa, Sockel, Katja, Ruhnke, Leo, Brückner, Stefan, Sommer, Ulrich, Meier, Frieder, Röllig, Christoph, von Bonin, Malte, Thiede, Christian, Schetelig, Johannes, Bornhäuser, Martin, and Stölzel, Friedrich

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tah-10.1177_20406207221115005 for Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation by Desiree Kunadt, Sylvia Herold, David Poitz, Lisa Wagenführ, Theresa Kretschmann, Katja Sockel, Leo Ruhnke, Stefan Brückner, Ulrich Sommer, Frieder Meier, Christoph Röllig, Malte von Bonin, Christian Thiede, Johannes Schetelig, Martin Bornhäuser and Friedrich Stölzel in Therapeutic Advances in Hematology

Published
2022
Full Text
View/download PDF

143. Additional file 1 of Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Author

Eckardt, Jan-Niklas, Stölzel, Friedrich, Kunadt, Desiree, Röllig, Christoph, Stasik, Sebastian, Wagenführ, Lisa, Jöhrens, Korinna, Kuithan, Friederike, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, Zdenek, Mayer, Jiri, Kroschinsky, Frank, Berdel, Wolfgang E., Ehninger, Gerhard, Serve, Hubert, Müller-Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Schetelig, Johannes, Bornhäuser, Martin, Thiede, Christian, and Middeke, Jan Moritz

Abstract

Additional file 1: Impact of continuous variables on odds of EM manifestation and multivariable analysis for outcome.

Published
2022
Full Text
View/download PDF

144. Additional file 1 of Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Author

Kunadt, Desiree, Stasik, Sebastian, Metzeler, Klaus H., Röllig, Christoph, Schliemann, Christoph, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Scholl, Sebastian, Hilgendorf, Inken, Brümmendorf, Tim H., Jost, Edgar, Steffen, Björn, Bug, Gesine, Einsele, Hermann, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Krause, Stefan W., Hänel, Mathias, Hanoun, Maher, Kaufmann, Martin, Wörmann, Bernhard, Kramer, Michael, Sockel, Katja, Egger-Heidrich, Katharina, Herold, Tobias, Ehninger, Gerhard, Burchert, Andreas, Platzbecker, Uwe, Berdel, Wolfgang E., Müller-Tidow, Carsten, Hiddemann, Wolfgang, Serve, Hubert, Stelljes, Matthias, Baldus, Claudia D., Neubauer, Andreas, Schetelig, Johannes, Thiede, Christian, Bornhäuser, Martin, Middeke, Jan M., and Stölzel, Friedrich

Abstract

Additional file 1: Table S1 Overview of the clinical trials the study patients were selected from. Figure S1 Forrest Plot of variables evaluated in univariate analysis. Multivariate Cox proportional hazard regression for (A) overall survival and (B) relapse-free survival.

Published
2022
Full Text
View/download PDF

145. Akute Myeloische Leukämie (AML)

Author

Schweizerische Gesellschaft Für Hämatologie, Schlenk, Richard Friedrich, Heuser, Michael, Schweizerische Gesellschaft Für Medizinische Onkologie, Gesellschaft Für Pädiatrische Onkologie Und Hämatologie, Manz, Markus G., Reinhardt, Dirk, Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Greil, Richard, Braess, Jan, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Beelen, Dietrich W., Passweg, Jakob R., and Röllig, Christoph

Subjects
Medizin und Gesundheit
Published
2022
Full Text
View/download PDF

146. Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies

Author

Kirschner, Martin, Rolles, Benjamin, Kricheldorf, Kim, Vieri, Margherita, Begemann, Matthias, Maurer, Angela, Wlodarski, Marcin W., Sahoo, Sushree S., Brümmendorf, Tim Henrik, Jost, Edgar, Beier, Fabian, Crysandt, Martina, Röllig, Christoph, Stölzel, Friedrich, Kramer, Michael, Bornhäuser, Martin, Serve, Hubert, Platzbecker, Uwe, and Müller-Tidow, Carsten

Subjects
Hematology
Abstract

HemaSphere: open access journal of the European Hematology Association 6(11), 1-5 (2022). doi:10.1097/HS9.0000000000000787, Published by Wolters Kluwer Health, [Philadelphia, Pennsylvania]

Published
2022
Full Text
View/download PDF

148. Large case-control study indicates no association of KIRgenotype and risk of developing acute myeloid leukemia

Author

Heidenreich, Falk, Falk, Bose, Baldauf, Henning, Massalski, Carolin, Schäfer, Gesine, Rücker-Braun, Elke, Altmann, Heidi, Sauter, Jürgen, Solloch, Ute V., Lange, Vinzenz, Stölzel, Friedrich, Röllig, Christoph, Middeke, Jan M., von Bonin, Malte, Thiede, Christian, Schäfer-Eckart, Kerstin, Müller-Tidow, Carsten, Krause, Stefan W., Kraus, Sabrina, Kaufmann, Martin, Hänel, Mathias, Serve, Hubert, Neubauer, Andreas, Bornhäuser, Martin, Schmidt, Alexander H., and Schetelig, Johannes

Abstract

•This large case-control study reveals no differences in the KIRand KIR-ligand genotype frequencies among patients with and without AML.•Results suggest steady-state KIR-mediated NK cell immunity does not define risk of AML, and NK immunity is disarmed as leukemic clones grow.

Published
2023
Full Text
View/download PDF

149. Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse

Author

Sockel, Katja, primary, Stölzel, Friedrich, additional, Hönl, Franziska, additional, Baldauf, Henning, additional, Röllig, Christoph, additional, Wermke, Martin, additional, von Bonin, Malte, additional, Teipel, Raphael, additional, Link-Rachner, Cornelia, additional, Brandt, Kalina, additional, Kroschinsky, Frank, additional, Hänel, Mathias, additional, Morgner, Anke, additional, Klesse, Christian, additional, Ehninger, Gerhard, additional, Platzbecker, Uwe, additional, Bornhäuser, Martin, additional, Schetelig, Johannes, additional, and Middeke, Jan Moritz, additional

Published
2022
Full Text
View/download PDF

150. Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation

Author

Kunadt, Desiree, primary, Herold, Sylvia, additional, Poitz, David, additional, Wagenführ, Lisa, additional, Kretschmann, Theresa, additional, Sockel, Katja, additional, Ruhnke, Leo, additional, Brückner, Stefan, additional, Sommer, Ulrich, additional, Meier, Frieder, additional, Röllig, Christoph, additional, von Bonin, Malte, additional, Thiede, Christian, additional, Schetelig, Johannes, additional, Bornhäuser, Martin, additional, and Stölzel, Friedrich, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results